Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)

Inclusion Criteria:

• Participants with Asymptomatic Plasmodium falciparum Malaria with no Fever or othersign of Acute Uncomplicated Malaria and, with Microscopic confirmation usingGiemsa-stained thick film, and a Parasitemia of >= 40 to <= 10,000 AsexualParasites/Microliter (μL) of Blood.

• Axillary Temperature < 37.0 degree Celcius (ºC) or oral/Tympanic/rectal Temperature< 37.5ºC; without history of fever during the previous 48 hours.

• Have a body weight >= 45 kilogram (kg)

• Participants capable of giving Signed Informed consent which includes Compliancewith the requirements and restriction listed in the Informed consent form

• Other Protocol defined Inclusion Criteria could apply

Exclusion Criteria:

• Participants with any disease requiring Chronic Treatment

• Participants with any Preplanned surgery during the study

• Participants with any previous Treatment with pyronaridine as part of a combinationtherapy during the last 3 months

• Participants with any adequate Hematological, Hepatic, and renal function as definedin the Protocol

• Other protocol defined Exclusion Criteria could apply